-
Nature Sub-Journal | Chen Jun and other teams from Fudan University develop new nanomaterials to target tumors that have metastasized throughout the body
Time of Update: 2021-06-05
Metastasis involves three steps: (i) tumor cells infiltrate the circulatory system from the primary site through epithelial-mesenchymal transition (EMT), (ii) circulating tumor cells (CTC) and platelets form "microthrombi" to avoid immune surveillance in the circulation , And (iii) CTC is colonized in the niche before the transfer.
-
China is the largest country with lung cancer, while the United States has benefited from tobacco control, and cancer death rates have fallen sharply | World No Tobacco Day
Time of Update: 2021-06-04
Today, with the reduction of smoking and the improvement of early screening and treatment, the cancer mortality rate in the United States has continued to decline from 1991 to 2018, with an overall decrease of 31%.
-
The initial application, the strength is full: the superior curative effect of Disumab, helps the sustained benefit of lung cancer bone metastasis
Time of Update: 2021-06-04
In the treatment of bone metastases, the patient's blood calcium, blood phosphorus, and alkaline phosphatase returned to normal after 1 month of treatment with desulumab, and the bone destruction was significantly improved after 2 cycles, and the pain score was also reduced from 7 to 2 , The pain symptoms disappeared after 6 months of treatment, and there was no obvious abnormality in the vertebral body radioactivity distribution after 8 cycles.
-
Brit J Cancer: The relationship between exercise, grip strength, sedentary behavior and the incidence of malignant melanoma
Time of Update: 2021-06-04
Researchers explored the relationship between exercise, grip strength, and sedentary behavior and the risk of malignant melanoma, and used the data analysis of this prospective cohort study Related confounding factors.
Association between physical activity, grip strength and sedentary behaviour with incidence of malignant melanoma: results from the UK Biobank .
-
CD25 ADC shows positive treatment results in phase 1 clinical | Yimai Meng broke the news
Time of Update: 2021-06-04
★Pharmaceutical financingVenus Biosciences today completed hundreds of millions of RMB in Pre-A+ round of financing , CICC-Qide’s exclusive lead investment June 1, 2021/eMedClub News/--Recently, a commercial biotechnology company ADC Therapeutics announced its new anti-conjugate drug (ADC) camidanlumab targeting CD25 The results of the Phase 1 clinical trial of tesirine (Cami) were published on The Lancet Haematology, which is mainly used to treat relapsed/refractory Hodgkin and non-Hodgkin's lymphoma.
-
Metz Tumor Progress Express (Issue 007)
Time of Update: 2021-06-04
The results of this study showed that in high-risk locally advanced head and neck squamous cell carcinoma patients, adding avelumab to concurrent chemoradiation did not improve the progression-free survival of patients.
-
The first KRAS inhibitor has been approved under accelerated approval, and the target of a non-preparable drug is counterattack, and a variety of drugs are on the way
Time of Update: 2021-06-04
Long press the QR code to receive on May 28, 2021, the FDA announced the accelerated approval of the KRAS inhibitor Lumakras (sotorasib, AMG510) [1] for the treatment of non-small cell lung cancer (NSCLC) patients with KRAS G12C mutations.
-
Cell: Harvard Medical School confirmed that obesity suppresses immune cells and accelerates tumor growth
Time of Update: 2021-06-04
Overexpression of PHD3 protein can effectively reverse the suppression of tumor immune cells caused by high-fat diet, which is expected to become a new target for cancer treatment.
-
When does colorectal cancer screening start?
Time of Update: 2021-06-04
In this topic, based on existing guidelines and high-quality evidence, experts and scholars mainly discussed the difficult and difficult problems in colorectal cancer (CRC) screening, such as the timing of screening, the choice of screening technology, and how to deal with negative colonoscopy results Wait.
-
Nature Reviews Drug Discovery: What are the challenges for CAR-T therapy to overcome solid tumors?
Time of Update: 2021-06-04
Relevant results were published on Science, details: CAR-T overcomes the qualitative leap of solid tumors, only killing cancer cells, not healthy cellsIn addition to the above research, scientists have also designed a variety of other "molecular switches", their functions include allowing CAR-T cells to recognize a variety of different antigens; inactivation after recognizing antigens expressed by healthy cells; or through The drug regulates the activity of CAR-T cells.
-
[Nature Sub-Journal] Reactivation of "paralyzed" immune cells | Innovative therapy for glioma is here!
Time of Update: 2021-06-04
To this end, researchers have developed an innovative therapy that reactivates the "paralyzed" immune system to fight tumors and prolongs the lives of mice with IDH mutant tumors.
-
ASCO 2021: Summary Overview and Prospects 17 | Major Progress in Research on Hepatocellular Carcinoma (Phase 2)
Time of Update: 2021-06-04
This study aims to understand the decision-making factors of patients with adjuvant treatment after hepatocellular carcinoma ( HCC ) resection in China .
Factors influencing adjuvant treatment decision making among Chinese patients with hepatocellular carcinoma (HCC): Results of a patient survey.
-
ASCO 2021: Summary Overview and Outlook 15 | Overview of Latest Breast Cancer Research (ER Positive Breast Cancer Column)
Time of Update: 2021-06-04
EndoPredict clinical verification in premenopausal women with estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) primary breast cancerBackground: EndoPredict 12 gene prognostic analysis has been verified to predict the remote recurrence-free survival (DRFS) and response to chemotherapy in postmenopausal women with ER+ and HER2- breast cancer.
-
Can antibiotics treat cancer?
Time of Update: 2021-06-04
Mankin said: "Since we know that this idea is theoretically feasible, we can first find some antibiotics that can bind to unmodified eukaryotic ribosomes, and then It is optimized so that it can specifically inhibit the synthesis of harmful proteins.
-
ASCO 2021: Summary Overview and Outlook 19 | Overview of Latest Breast Cancer Research (Triple Negative Breast Cancer Column)
Time of Update: 2021-06-04
According to PD-L1 expression, dendritic cell vaccine added to neo-assistant CT Effect on the complete pathological response of patients with early breast cancerBreast cancer (BC) exhibits a naive and capable immune system in the early stage.
-
Progress of bispecific antibodies in the treatment of RRMM | ASCO prospects in 2021
Time of Update: 2021-06-04
According to the standards of the International Myeloma Working Group (IMWG), the overall response rate (ORR) of patients with a dose of ≥215 µg/kg is 75% (n=15/20), including partial response (PR, n=6), very Good partial remission (VGPR, n=3), complete remission (CR, n=1), strict complete remission (sCR, n=5); the median time to remission was 22 days, and 4 cases had previously received targeted Three (75%) patients treated with BCMA achieved remission (VGPR, n=2; sCR, n=1).
-
The effective rate of lung cancer treatment has increased by 2.5 times. How is it done?
Time of Update: 2021-06-04
In 2021, the American Society of Clinical Oncology ASCO reported a study that combined with PD-1 inhibitor pembrolizumab (Drug K) after concurrent radiotherapy and chemotherapy for stage III lung cancer can achieve a treatment response rate of 70%.
-
JCO: A predictive model for predicting the risk of breast cancer in childhood cancer survivors who have received chest radiotherapy
Time of Update: 2021-06-04
Menopausal women over the age of 40 who have received radiotherapy within one year of menarche and have a history of breast cancer among first-degree relatives have the highest risk of breast cancer.
-
10 classic cases, let you know the 72 changes of lung cancer!
Time of Update: 2021-06-04
Case 3: The patient, male, 82 years old, was admitted to the hospital with cough and chest pain for half a month.
Chest CT showed multiple nodules in the posterior segment of the right upper lung with enlarged right hilar lymph nodes, no obvious abnormalities in blood tumor markers, T-SPOT (+).
-
ASCO 2021: Summary Overview and Prospects 14|Special Research Progress of Non-Small Cell Lung Cancer (02)
Time of Update: 2021-06-04
Screening ImmunizationOriginal source: Germline mutations in patients with non-small cell lung cancer.
Real-world data on the results of continuous treatment regimens involving anti-PDx-1 in advanced and metastatic non-small cell lung cancerDoes the order matter?
